Germ cell tumors of the gonads: A selective review emphasizing problems in drug resistance and current therapy options

Oncology

Volumn 76, Issue 2, 2009, Pages 77-84

  Schrader, Mark ^a   Kempkensteffen, Carsten ^a   Christoph, Frank ^a   Hinz, Stefan ^a   Weikert, Steffen ^a   Lein, Michael ^a   Krause, Hans ^a   Stephan, Carsten ^a   Jung, Klaus ^a   Hoepfner, Michael ^a   Albers, Peter ^b   Miller, Kurt ^a   Schostak, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM KASSEL   (Germany)

Author keywords

Chemotherapy response; Germ cell cancer; Molecular targeted therapy

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PROTEIN P53; SUNITINIB; THALIDOMIDE; VINCRISTINE;

APOPTOSIS; CANCER THERAPY; CAUSE OF DEATH; CELL MEMBRANE; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DNA REPAIR; DRUG MEGADOSE; GERM CELL TUMOR; GONAD TUMOR; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEMINOMA; STRESS; THEORETICAL MODEL; TREATMENT RESPONSE; TUMOR CELL; URINARY TRACT CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; THALIDOMIDE;

EID: 58149102385     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187426     Document Type: Review

References (63)

1. Becker N, Wahrendorf J: Krebsatlas der Bundesrepublik Deutschland (Atlas of Cancer Mortality in Germany), ed 3. Berlin, Springer, 1998.
2. Einhorn LH, Donohue JP: Improved chemotherapy in disseminated testicular cancer. J Urol 1977;117:65-69.
3. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H: Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006;118:3099-3111.
4. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293-300.
5. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C: European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-1399.
6. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-1172.
7. Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, de Mulder P: Intensive inductionsequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692-701.
8. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-1293.
9. Bokemeyer C, Harstrick A, Beyer J, Metzner B, Ruther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schoffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pfluger KH, Ostermann H, Kanz L, Schmoll HJ: The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 1998;25(suppl 4):24-32, discussion 45-48.
10. Bajorin DF, Nichols CR, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Einhorn L, Mazumdar G, Bosl J, Motzer RJ: Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): a cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB (abstract). J Clin Oncol (Meeting Abstracts) 2006;24:4510.
11. Masters JR, Koberle B: Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003;3:517-525.
12. Oosterhuis JW, Andrews PW, Knowles BB, Damjanov I: Effects of cis-platinum on embryonal carcinoma cell lines in vitro. Int J Cancer 1984;34:133-139.
13. Parris CN, Arlett CF, Lehmann AR, Green MH, Masters JR: Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int J Radiat Biol Relat Stud Phys Chem Med 1988;53:599-608.
14. Pera MF, Friedlos F, Mills J, Roberts JJ: Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum (II) on DNA. Cancer Res 1987;47:6810-6813.
15. Parris CN, Walker MC, Masters JR, Arlett CF: Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. Cancer Res 1990;50:7513-7518.
16. Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002;99:14298-14302.
17. Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH, de Vries EG: Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 1995;71:684-690.
18. Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H: Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996;32A:1248-1253.
19. Hettinga JV, Lemstra W, Meijer C, Los G, de Vries EG, Konings AW, Kampinga HH: Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Int J Cancer 1996;67:800-807.
20. Richards EH, Hickey E, Weber L, Masters JR: Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 1996;56:2446-2451.
21. Richards EH, Hickman JA, Masters JR: Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br J Cancer 1995;72:620-626.
22. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
23. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
24. Lutzker SG, Mathew R, Taller DR: A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 2001;20:2982-2986.
25. Lutzker SG, Levine AJ: A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 1996;2:804-810.
26. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH: Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 2002;20:1551-1561.
27. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ: A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 2005;24:6090-6100.
28. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C: Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003;9:767-773.
29. Braun RE: Every sperm is sacred - or is it? Nat Genet 1998;18:202-204.
30. Chresta CM, Masters JR, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-1841.
31. L and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 1999;18:1457-1464.
32. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ: Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003;63:513-521.
33. Kempkensteffen C, Jager T, Bub J, Weikert S, Hinz S, Christoph F, Krause H, Schostak M, Miller K, Schrader M: The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. Int J Androl 2007;30:476-483.
34. Ohndorf UM, Whitehead JP, Raju NL, Lippard SJ: Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry 1997;36:14807-14815.
35. Trimmer EE, Zamble DB, Lippard SJ, Essigmann JM: Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry 1998;37:352-362.
36. Zamble DB, Mikata Y, Eng CH, Sandman KE, Lippard SJ: Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J Inorg Biochem 2002;91:451-462.
37. Zafarana G, Gillis AJ, van Gurp RJ, Olsson PG, Elstrodt F, Stoop H, Millan JL, Oosterhuis JW, Looijenga LH: Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res 2002;62:1822-1831.
38. Koberle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-276.
39. McGurk CJ, Cummings M, Koberle B, Hartley JA, Oliver RT, Masters JR: Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 2006;97:1121-1136.
40. Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J, Taron M, Rosell R, Baselga J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-528.
41. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ: Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006;7:67-88.
42. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-166.
43. Simon GR, Sharma S, Cantor A, Smith P, Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983.
44. Sève P, Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005;5:73-88.
45. Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005;92:259-264.
46. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M: Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997;65:130-137.
47. Bramson J, McQuillan A, Panasci LC: DNA repair enzyme expression in chronic lymphocytic leukemia vis-a-vis nitrogen mustard drug resistance. Cancer Lett 1995;90:139-148.
48. Chew SL, Baginsky L, Eperon IC: An exonic splicing silencer in the testes-specific DNA ligase III beta exon. Nucleic Acids Res 2000;28:402-410.
49. Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH: Xeroderma pigmentosum group A protein and chemotherapy resistance in human germ cell tumors. Lab Invest 2003;83:1489-1495.
50. Cleaver JE, Karplus K, Kashani-Sabet M, Limoli CL: Nucleotide excision repair 'a legacy of creativity'. Mutat Res 2001;485:23-36.
51. Rick O, Braun T, Siegert W, Beyer J: Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006;42:1775-1779.
52. Cairns J: Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 2002;99:10567-10570.
53. Paulus WE: Pharmacotherapy in pregnancy (in German). Ther Umsch 1999;56:602-607.
54. Voigt W, Kegel T, Maher G, Jordan K, Muller L, Schmoll HJ: Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HDICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006;17:531-533.
55. Jordan K, Kegel T, Mueller LP, Kinitz I, Schmol HJ: Feasibility of a combination of high dose chemotherapy ifosfamide, carboplatin, etoposide (ICE) plus stem cells and bevacizumab in refractory sarcoma and germ cell tumors (abstract). J Clin Oncol ASCO Meeting Abstracts 2005;23:9070.
56. Mauduit C, Hamamah S, Benahmed M: Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update 1999;5:535-545.
57. Gaemers IC, Sonneveld E, van Pelt AM, Schrans BH, Themmen AP, van der Saag PT, de Rooij DG: The effect of 9-cis-retinoic acid on proliferation and differentiation of a spermatogonia and retinoid receptor gene expression in the vitamin A-deficient mouse testis. Endocrinology 1998;139:4269-4276.
58. Gaemers IC, Van Pelt AM, Themmen AP, De Rooij DG: Isolation and characterization of all-trans-retinoic acid-responsive genes in the rat testis. Mol Reprod Dev 1998;50:1-6.
59. Gaemers IC, van Pelt AM, van der Saag PT, Hoogerbrugge JW, Themmen AP, de Rooij DG: Differential expression pattern of retinoid X receptors in adult murine testicular cells implies varying roles for these receptors in spermatogenesis. Biol Reprod 1998;58:1351-1356.
60. Lamb DJ: Growth factors and testicular development. J Urol 1993;150:583-592.
61. Huckins C: The spermatogonial stem cell population in adult rats. I. Their morphology, proliferation and maturation. Anat Rec 1971;169:533-557.
62. Dym M: Spermatogonial stem cells of the testis. Proc Natl Acad Sci USA 1994;91:11287-11289.
63. Yoshinaga K, Nishikawa S, Ogawa M, Hayashi S, Kunisada T, Fujimoto T, Nishikawa S: Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function. Development 1991;113:689-699.